I try to present a coherent argument when I publish my XLH essays, with a theme and logic and conclusion, sometimes even a call to action. But I also have some random thoughts about the XLH life, thoughts that are still forming, perhaps going nowhere, but perhaps just waiting for additional insights that would inform…
Author: giniajo@gmail.com
Reading the science
So, you’ve read everything you can find about XLH at various reliable websites, but you want to know more. One option is to read what your health care providers are (or aren’t) reading about current research and the overall scientific understanding of XLH. But perhaps you don’t know where to start, so here’s a quick…
Coding for the future
We’re in the really early days of artificial intelligence (AI) being used extensively in health care, and while I can see some great potential, I worry that it’s all built on flawed assumptions. Research by AI often depends with billing codes, known as ICD codes (the most current of which are known as ICD10). There’s…
Autosomals get some attention
There’s a new journal article on Autosomal dominant hypophosphatemia that reports on one patient and collects the literature specific to that form of chronic hypophosphatemia. It’s useful to have the citations to the very limited relevant literature collected in one spot, but the article itself is problematic for the patient community (including both autosomal and…
Reliable sources
The XLH community is an enticing one for both legit research and scammers. Researchers have been fascinated by FGF23 ever since it was discovered by, among others, Dr. Michael Econs, a prominent XLH researcher (and I’m told that researchers into another rare bone disorder, fibrous dysplasia, were simultaneously involved in that discovery). Excessive FGF23 production…
Bright future
In recent years, with the development of a class of treatments called “monoclonal antibody,” a whole new world of treatment options has opened up, and much of that world is populated by rare disorders like XLH. A monoclonal antibody is an antibody (no kidding, right?) that’s is cloned from a single specific cell. It’s designed…
Words matter
This is a plea to all who write or talk about XLH (and the other genetic hypophosphatemias), including patients, clinicians, researchers, editors, and academics (and anyone else I’ve forgotten): update your terminology to reflect current understanding of the disorder. First, stop calling the various chronic hypophosphatemic disorders “a form of rickets” or “hypophosphatemic rickets.” These…
Standard of care
Lawyers use the term “standard of care” slightly differently from the medical profession, but in both cases, it refers to the bare minimum of care that one person owes to another to avoid liability. In the law, it’s usually based on a “reasonable person” test — what would a reasonable person do in the circumstances?…
Rare bedside manner
Patients pay the price when clinicians don’t treat us like human beings deserving of respect. The frustrating thing is, it’s really not that hard to do better. Along with the rule of “First, do no harm,” just follow the Golden Rule: “Treat others as you wish to be treated yourself.” In my experience, clinicians break…
What’s my story?
Some of you know me from the XLH listserv days when I was a frequent poster and also the subscription manager. But if you’re newer to the community, you may be wondering, who is this person who thinks she understands at least some of the XLH experience? So let me share a little of my…